FTM may not always be the best with which to work. Even though many editing features are out there, not all offer a straightforward solution. We developed DocHub to make editing easy, no matter the form format. With DocHub, you can quickly and effortlessly rework pecularity in FTM. On top of that, DocHub gives a range of additional tools including document generation, automation and management, sector-compliant eSignature solutions, and integrations.
DocHub also helps you save time by creating document templates from documents that you utilize frequently. On top of that, you can take advantage of our numerous integrations that allow you to connect our editor to your most used apps easily. Such a solution makes it quick and easy to work with your documents without any delays.
DocHub is a useful feature for individual and corporate use. Not only does it offer a all-encompassing suite of capabilities for document generation and editing, and eSignature integration, but it also has a range of features that prove useful for creating multi-level and streamlined workflows. Anything uploaded to our editor is kept risk-free in accordance with leading field standards that shield users' data.
Make DocHub your go-to choice and streamline your document-centered workflows easily!
my name is Fritz VRI I work at the Myoma Center at the University of Arkansas for medical sciences and weamp;#39;ve been interested in detecting small numbers of Myoma cells in the bowar of patients who are by standard criteria incomplete remiss this is called looking for minimal residual disease so these are small amounts of my in the marrow and we look at the significance of detecting these um so weamp;#39;ve been doing this testing systematically uh since 2013 uh on all our patients and weamp;#39;ve done a study of over 1700 patients looking at uh approximately 20,000 tests and try to identify the meaning uh of the presence of these small number uh of myom cells in the B arrow that is called a positive mrd test or positive minimal reging disease test now the good news is that we found that patients who have negative mrds just persistently seral on at least three occasions in the first five years after transplant have a very low risk of relapse on long-term followup so if
